Healthcare With Altitude: PACS Delivers, and Salt Lake City Joins the Big‑Cap Conversation -( $PACS ) by John F. Heerdink, Jr. 3 days ago Read more Family Offices Put On The White Coat: Why The Smart Money Is Suddenly Fluent In AI & Oncology by John F. Heerdink, Jr. 3 days ago Read more From Weekly Jabs to Yearly Scopes: Why Eupraxia’s EP‑104GI Might Have Sanofi Checking Its Calendar – ( $EPRX $SNY $XBI ) by John F. Heerdink, Jr. May 6, 2026 Read more Telehealth After the Sugar High: Why Amwell Thinks Its Platform Days Are Just Getting Started -( $AMWL $DOCS $HIMS $TALK $TDOC ) by John F. Heerdink, Jr. May 5, 2026 Read more Amwell Positions for Profitability Push as Telehealth Sector Eyes Explosive Growth -( $AMWL $TDOC ) by John F. Heerdink, Jr. May 4, 2026 Read more From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK ) by John F. Heerdink, Jr. May 4, 2026 Read more GLP-1s, Hairlines, and the Almost-Pumpers: Why Modular Medical May Be Ready for Its Close-Up -( $LLY $MODD ) by John F. Heerdink, Jr. May 2, 2026 Read more Winning in the New FDA Era: Why Modular Medical’s Pivot Could Turn “Almost‑Pumpers” into Believers -( $MODD $PODD ) by John F. Heerdink, Jr. May 1, 2026 Read more Italy’s Chiesi Group’s $1.9 Billion KalVista Buy: A Rare-Disease Power Play With Real Teeth -( $XBI $IBB ) by John F. Heerdink, Jr. April 29, 2026 Read more Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB ) by John F. Heerdink, Jr. April 29, 2026 Read more Read more
